VABYSMOⓇ
@vabysmo-hcp.com
Review information for healthcare providers about VABYSMO® (faricimab-svoa) for nAMD, DME, and RVO. See full safety for more information.
VABYSMOⓇ's Company Logos
VABYSMOⓇ's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#E6E7E6
Gray Nurse
230, 231, 230
120, 2, 90
0, 0, 0, 9
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About VABYSMOⓇ
Genentech offers VABYSMO™ (faricimab-svoa), the first and only dual-pathway treatment for Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO). Their innovative product provides powerful first-line efficacy, achieving superior results compared to aflibercept in BCVA improvement across all indications. VABYSMO ensures rapid and sustained drying with significant CST reductions over time in DME, nAMD, and RVO.
The treatment offers a flexible dosing regimen, ranging from monthly to extended intervals, tailored to individual patient needs. With a focus on safety and efficacy, VABYSMO emphasizes the importance of proper monitoring for adverse reactions and potential risks, ensuring comprehensive care for patients. For healthcare providers seeking effective and reliable solutions, VABYSMO stands out as a cutting-edge treatment option with proven clinical data and expert support
